CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor–Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

PURPOSE: In patients taking tamoxifen, the CYP2D6 genotype causes different exposure of active metabolite endoxifen. The objective of this randomized, open-label, multicenter, phase II study was to prospectively evaluate whether CYP2D6 genotype–guided tamoxifen dosing in patients with hormone recept...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Tamura, Kenji, Imamura, Chiyo K., Takano, Toshimi, Saji, Shigehira, Yamanaka, Takeharu, Yonemori, Kan, Takahashi, Masato, Tsurutani, Junji, Nishimura, Reiki, Sato, Kazuhiko, Kitani, Akira, Ueno, Naoto T., Mushiroda, Taisei, Kubo, Michiaki, Fujiwara, Yasuhiro, Tanigawara, Yusuke
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2020
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7030889/
https://ncbi.nlm.nih.gov/pubmed/31821071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01412
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge